Novo Nordisk STEP Young Phase 3 meets primary endpoint
Novo Nordisk’s STEP Young Phase 3 trial met its primary endpoint for semaglutide, with greater BMI reduction reported.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.